We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim Weighs in on Proposed Electronic Drug Tracing Program
Boehringer Ingelheim Weighs in on Proposed Electronic Drug Tracing Program
Boehringer Ingelheim (BI) has joined others calling on the FDA to modify some details of its proposed enhanced electronic drug distribution security program.